



ASX Announcement
29 October 2020

Presentation at Australia Biotech Invest & Partnering 2020

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') is pleased to announce that the Company's CEO and Executive Chairman, Mr Darren Lurie, will be presenting at AusBiotech's Australia Biotech Invest & Partnering 2020 between 10.30am – 11.10am (AEDT) today.

The conference is AusBiotech's leading one-day investment conference focused on trends in life sciences providing an opportunity for the Company to present to an audience of investors, research analysts and brokers, as well as industry executives from major global medical technology companies. Due to the current Covid-19 travel restrictions, the 2020 programme will be delivered via AusBiotech's digital platform. There will be an 8-minute Company presentation followed by a live group Q&A session moderated by Scott Power, Senior Healthcare Analyst at Morgans.

A copy of the Company's presentation is attached to this announcement.

- ends -

This announcement has been authorised for release by the Board of OIL.

For investor queries, please contact:

Darren Lurie
CEO and Executive Chairman – Optiscan Imaging Limited
E: dlurie@optiscan.com

About Optiscan

Optiscan is a global leader in the development of microscopic imaging and related technologies for screening, surgery and medical research. Based in Melbourne, Australia, Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level – instant "virtual biopsies" with applications for cancer screening and surgical margin determination. Optiscan's technology has the capability to improve patient welfare, reduce hospital costs, improve accuracy and reduce the need for multiple procedures. The technology is approved for use in brain surgery and is involved in a number of oral cancer and breast cancer studies.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia



Optiscan Imaging Ltd (ASX:OIL)

Enabling “Real-time Virtual Biopsy” for
Human Cancer Screening and Surgical
Margin Detection

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 25 October 2020.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Notice

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Corporate Snapshot

Board

Darren Lurie – Executive Chairman

B.LLB (Hons) and B.COM (Hons)

Executive Chair since May 2018. Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia). Darren is a former chair and non-executive director of ASX listed Farm Pride Foods Ltd (ASX:FRM).

Dr Philip Currie – Non Executive Director

MBBS (Hons), FRACP, MBA

Dr Currie is a leading cardiologist with more than 35 years experience in medical research, clinical cardiology and business. He completed his cardiology fellowship at the prestigious Mayo Clinic, staff cardiologist at both Mayo Clinic and Cleveland Clinic and was the Director of Echocardiography at Michigan Heart and Vascular Institute.

Graeme Mutton – Non Executive Director

CPA

Graeme is a long-standing shareholder in Optiscan and has a deep understanding of Optiscan's technology and applications. He is a former manager of an accounting practice and successful business owner and operator.


Total Securities on Issue

- 596,730,300 Ordinary Shares
- 25,600,000 unlisted options

Market Capitalisation: ~A\$66million @11c*

* As at 25 October 2020

Capital Raising: \$9.8m @8.25c in September 2020




OPTISCAN Introduction - Technology

- Hand-held Confocal Endomicroscope for Medical and Research Imaging**
- World-leading and Patent Protected**
- Real-time “Virtual Biopsy”**
- Reduced and More Targeted Biopsies**
- Capture all Cancer Cells and reduce Tumour Margin in Surgery**

Optiscan FIVE2 Laboratory and InVivage® Clinical Systems



**FIVE2 (ViewnVivo)
Laboratory System**



**InVivage® Clinical System
For Oral & Breast Cancer**

Optiscan Applications and Devices

Clinical Applications and Devices:

- Oral Cancer - InVivage[®]
- Breast Cancer - InVivage[®]
- Neurosurgery – CONVIVO[®] (Carl Zeiss Meditec Co-operation)

Pre-clinical Device: FIVE2 (ViewVivo[®])

- Laboratory & Translational Experiments
- Medical Research Facilities and Universities

World Lip & Oral Cavity Cancer Incidence and Mortality

2%

Of all cancer
Incidence

350k

New cases
in 2018

177k

Total deaths
in 2018

>80%

Survival

Early Diagnosis

57%

Survival

Late Diagnosis

2.5x

Cost

Early Vs Late

Oral Cancer Market Size

China

48 Public Tertiary Dental Hospitals

Guangdong Province:

158 Stomatology Departments in General Hospitals

14 Public and Private Dental Hospitals


Name	Location	No. of Chairs	Patient Volume (Out patient annually)
Hospital of Stomatology, PKU	Beijing	569	1,453,000
Hospital of Stomatology, Sichuan University	Chengdu, Sichuan Province	350	750,000
Hospital of Stomatology, The 4 th Military Medical University	Xi'an, Shaanxi Province	270	500,000
Hospital of Stomatology, Wuhan University	Wuhan, Hubei Province	450	960,000
Hospital of Stomatology, Jilin University	Changchun, Jilin Province	195	255,550
Guanghua Hospital of Stomatology, Sun Yat-sen University	Guangzhou, Guangdong Province	326	360,000

United States

900 Specialist Cancer Centers

6,146 Total US Hospitals

9,000 Oral and Maxillofacial Surgeons



OPTISCAN – Oral Cancer Progress

3 Oral Cancer Studies and Trials

- Received Federal Government ~1m A\$ grant for 150 patient Oral Cancer Study at Melbourne Dental School (includes \$260k payable to Optiscan)
- Trial on-going at the Memorial Sloan Kettering Cancer Centre in New York
- Trial on-going at the Australian Centre for Oral Oncology in Perth

United States FDA Regulatory Approval Activity

- Met with US FDA in January 2020 and further submission in June 2020 to receive feedback on proposed content and format for a 510(k) clearance submission
- FDA 510(k) submission planned for first half of 2021

Breast Cancer - Most Common Cancer in Women

**2.1
Million**

2.1 million new cases of breast cancer predicted in 2018 (globally)¹

15%

15% of all new Cancer cases in United States are breast cancer²

8.5%

8.5% of all new cancer cases in China are breast cancer³

- 20-30% of lumpectomy patients currently require repeat surgery with current practice (histopathology analysis) often taking up to 3-4 days post initial surgery.
- Submission made to Ethics Committee of leading Melbourne Hospital for approval of Stage 3 of Breast Cancer Intraoperative Assessment Trial.

■ CONVIVO® – Carl Zeiss Meditech (CZM) Co-operation

- ❑ FDA 510(k) clearance and CE Mark obtained
- ❑ “this probably is the most exciting technology that I have seen in my career come through the laboratory.” - Mark C Preul, Neurosurgeon, Barrow Neurosurgical Institute, Arizona, United States.



Distribution Model for the Preclinical Device (FIVE2)

□ Asia Pacific Distribution Manager- Dr Joseph Jiafu, PhD


□ China Distribution Manager- Wei Zhu, BSc

- South and West China: Guangzhou Yunxing
- East China: Biotimes Technology Limited

3 Sales since late 2019

□ North America Distribution

- Technical, Marketing and Sales: Advanced Microscopy Consultancy Services



Outlook

- Commencement of 150 patient Oral Cancer Study at the Melbourne Dental School.
- Commencement of Stage 3 of breast cancer trial at leading Melbourne hospitals
- Increased geographical footprint to deliver additional FIVE2 (ViewnVivo) sales
- FDA 510(k) Oral imaging submission planned for first half of 2021

Darren Lurie
Executive Chairman
Optiscan Imaging Limited
(ASX:OIL)

www.optiscan.com